Clinical trial
A Phase 1 Study of SynKIR-310, Autologous T Cells Transduced With CD19 KIR-CAR, in Participants With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
NCT06544265 is registered in ClinicalTrials.gov with Verismo Therapeutics as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1 Study of SynKIR-310, Autologous T Cells Transduced With CD19 KIR-CAR, in Participants With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
- Lead sponsor
- Verismo Therapeutics
- Phase
- Phase 1
- Overall status
- Recruiting
- Start date
- November 1, 2024
- Completion date
- December 31, 2028
- Enrollment
- 36 (estimated)
- Sites
- 5
Conditions
As the registry lists them; a condition with its own page is linked.
aggressive b-cell non-hodgkin lymphoma, b cell lymphoma, diffuse large b cell lymphoma, dlbcl, dlbcl (diffuse large b-cell lymphoma) associated with chronic inflammation, dlbcl - diffuse large b cell lymphoma, epstein-barr virus positive dlbcl, nos, follicular lymphoma, follicular lymphoma grade 3, follicular lymphoma grade 3b, hgbl with myc and bcl2 and/or bcl6 rearrangements, high grade b-cell lymphoma, not otherwise specified, high-grade b-cell lymphoma, indolent b-cell non-hodgkin lymphoma, large b-cell lymphoma, mantle cell lymphoma, marginal zone lymphoma, marginal zone splenic lymphoma, nhl, adult, non-hodgkin lymphoma,b cell, primary mediastinal large b-cell lymphoma (pmbcl), refractory non-hodgkin lymphoma, relapsed non-hodgkin lymphoma, t-cell/histiocyte rich lymphoma, waldenstrom macroglobulinaemia, waldenstrom macroglobulinemia